Infections in myelodysplastic syndromes

Haematologica

Volumn 97, Issue 10, 2012, Pages 1459-1470

  Toma, Andréa ^a   Fenaux, Pierre ^b   Dreyfus, François ^c   Cordonnier, Catherine ^a,d  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c APHP Paris 6 University ^*  (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Bacterial; Infection; Myelodysplastic syndromes; Prophylaxis; Therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIBIOTIC AGENT; AZACITIDINE; CD11B ANTIGEN; CD18 ANTIGEN; CYTARABINE; DAUNORUBICIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; L SELECTIN; LENALIDOMIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; POSACONAZOLE; REACTIVE OXYGEN METABOLITE; TRIAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY PRODUCTION; APOPTOSIS; B LYMPHOCYTE; BACTERIAL INFECTION; DEATH; FEBRILE NEUTROPENIA; FEVER; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFECTION RISK; IRON CHELATION; IRON OVERLOAD; LYMPHOCYTE FUNCTION; MORBIDITY; MORTALITY; MYCOSIS; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; PHAGOCYTOSIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SEPSIS; SEPTICEMIA; SIDE EFFECT; T LYMPHOCYTE; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; COMMUNICABLE DISEASES; HUMANS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA;

EID: 84867241273     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.063420     Document Type: Review

References (182)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19): 1872-85.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.
3. Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev. 2009;23(Suppl 1):S15-9.
4. Kantarjian H, Issa JPJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006;106(8):1794-80.
5. Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant. 2009;43(8): 597-609.
6. Cunningham I, MacCalum SJ, Nicholls MD, Byth K, Hewson JW, Arnold B, et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol. 1995;90(3):602-6.
7. Ganser A, Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol Oncol Clin North Am. 1992;6(3):607-18.
8. Mufti GJ, Galton DAG. Myelodyslastic syndrome natural history and features of prognostic significance. Clin Haematol. 1986; 15(4):953-69.
9. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116(9):2174-9.
10. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;10(28):2847-52.
11. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Ochimar-Reissig R, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J CIin Oncol. 2002;20 (10):2429-40.
12. Silverman LR, McKenzie DR, Peterson BL, Holland JC, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-903.
13. Fenaux P, Mufti JG, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
14. Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes. Cancer. 2010;116(6):1485-94.
15. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011;29(5):516-23.
16. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low-dose 5-Aza- 2'-Deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J CIin Oncol. 2000;18(5):956-62.
17. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5- aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103 (5):1635-40.
18. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of lowdose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52-7.
19. Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403-11.
20. Acquaviva C, Gelsi-Boyer V, Birnbaum D. Myelodysplastic syndromes: lost between two states? Leukemia. 2010;24(1):1-5.
21. Vardiman J, Thiele J, Arber D, Brunning R, Borowitz M, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
22. Briggs R, Shults K, Flye L, McClintock-Treep S, Jagasia M, Goodman S, et al. Dysregulated human myeloid nuclear differentiation antigen expression in myelodysplastic syndromes: evidence for a role in apoptosis. Cancer Res. 2006;66(9):4645-51.
23. Mundle S, Venugopal P, Cartlidge J, Pandav D, Broady-Robinson L, Gezer S, et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996;88(7):2640-7.
24. Shetty V, Hussaini S, Broady-Robinson L, Allampallam K, Mundle S, Borok R, et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood. 2000;96(4):1388-92.
25. Claessens Y, Bouscary D, Dupont J, Picard F, Melle J, Gisselbrecht S, et al. In Vitro Proliferation and Differentiation of Erythroid Progenitors from Patients with Myelodysplastic Syndromes: Evidence for Fas - Dependent Apoptosis. Blood. 2002; 99(5):1594-601.
26. Hellström-Lindberg E, Kanter-Lewensohn L, Øst A. Morphological Changes and Apoptosis in Bone Marrow from Patients with Myelodysplastic Syndromes Treated with Granulocyte-CSF and Erythropoietin. Leuk Res. 1997;21:415-25.
27. Hellström-Lindberg E, Schmidt Mende J, Forsblom A, Christensson B, Fadeel B, Zhlvotovsky B. Apoptosis in Refractory Anaemia with Ringed Sideroblasts is Initiated at the Stem Cell Level and Associated with Increased Activation of Caspases. Br J Haematol. 2001;112(3):714-26.
28. Tehranchi R, Fadeel B, Forsblom A, Christensson B, Samuelsson J, Zhivotovsky B, et al. Granulocyte Colony - Stimulating Factor Inhibits Spontaneous Cytochrome C Release and Mitochondria - Dependent Apoptosis of Myelodysplastic Syndrome Hematopoietic Progenitors. Blood. 2003; 101(3):1080-6.
29. Tehranchi R, Fadeel B, Schmidt-Mende J, Forsblom A, Emanuelsson E, Jadersten M, et al. Antiapoptotic Role of Growth Factors in the Myelodysplastic Syndromes: Concordance Between in Vitro and in Vivo Observations. Clin Cancer Res. 2005;11(17): 6291-9.
30. Raza A, Gezer S, Mundle S, Gao X, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndrome. Blood. 1995;86 (1):268-75.
31. Rajapaksa R, Ginzton N, Rott L, Greenberg P. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Leukemia. 2010;24(1):1-5.
32. Barrett A, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia; distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000;37(1):15-29.
33. Karcher D, Frost A. The bone marrow in human immunodeficiency virus (HIV)-related disease. Morphology and clinical correlation. Am J Clin Pathol. 1991;95(1):63-71.
34. Smith M, Smith J. The occurrence subtype and significance of hematopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res. 1991;15(7):597-601.
35. Voulgarelis M, Giannouli S, Ritis K, Tzioufas A. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest. 2004;34(10):690-700.
36. Shetty V, Mundle S, Raza A. Pseudo Pelger- Huet anomaly in myelodysplastic syndrome: hyposegmented or apoptotic neutrophil? Blood. 2001;98(4):1273-5.
37. Prodan M, Tulissi P, Perticarari S, Presani G, Franzin F, Pussini E, et al. Flow cytometric assay for the evaluation of phagocytosis and oxidative burst of polymorphonuclear leukocytes and monocytes in myelodysplastic disorders. Haematologica. 1995;80(3):212-8.
38. Fianchi L, Leone G, Posteraro B, Sanguinetti M, Guidi F, Valentini C, et al. Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. Leuk Res. 2012;36(3):331-3.
39. Itoh Y, Kuratsuji K, Aizawa S, Sai M, Ohyashiki K, Toyama K. Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome. Ann Hematol. 1991;63(5):270-5.
40. Mazzone A, Porta C, Fossati G, Gritti D, Mazzucchelli I, Ricevuti G. Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. Leuk Lymphoma. 1996;23(3-4):267-75.
41. Ricevuti G, Mazzone A, Pasotti D, Fossati G, Mazzucchelli I, Notario A. The role of integrins in granulocyte dysfunction in myelodysplastic syndrome. Leuk Res. 1993; 17(7):609-19.
42. Ohsaka A, Saionji K, Igari J, Watanabe N, Iwabuchi K, Nagaoka I. Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes. Br J Haematol. 1997;98:108-13.
43. Elghetany M. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998;83(12):1104-15.
44. Elghetany M, Peterson B, MacCallum J, Nelson D, Varney J, Sullivan A, et al. Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leuk Res. 1997;21(9):801-6.
45. Ito Y, Kawanishi Y, Shoji N, Ohyashiki K. Decline in antibiotic enzyme activity of neutrophils is a prognostic factor for infection in patients with myelodysplastic syndrome. Clin Infect Dis. 2000;31(5):1292-5.
46. Moretti S, Lanza F, Spisani S, Latorraca A, Rigolin G, Giuliani A, et al. Neutrophils from patients with myelodysplastic syndromes: relationship between impairment of granular contents, complement receptors, functional activities and disease status. Leuk Lymphoma. 1994;13(5-6):471-7.
47. Bottcher T, Spreer A, Azeh I, Nau R, Gerber J. Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis. Neurosci Lett. 2003; 338(3):201-4.
48. Dubois B, Starckx S, Pagenstecher A, Oord J, Arnold B, Opdenakker G. Gelatinase B deficiency protects against endotoxin shock. Eur J Immunol. 2002;32(2):2163-71.
49. Yamada K, Yoshino K, Sekikawa K, Madarame H, Yagita H, Nakane A. Effect of a matrix metalloproteinase inhibitor on host resistance against Listeria monocytogenes infection. FEMS Immunol Med Microbiol. 2000;29(3):187-94.
50. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss D, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532-5.
51. Travaglino E, Benatti C, Malcovati L, Della Porta M, Gallì A, Bonetti E, et al. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol 2008;80(3):216-26.
52. Yamaguchi N, Ito Y, Ohyashiki K. Increased intracellular activity of matrix metallopro- teinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes. Ann Hematol. 2005;84(6):383-8.
53. Marisavljevic' D, Kraguljac N, Rolovic' Z. Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol. 2006;23(3):385-91.
54. Katsuki K, Shinohara K, Kameda N, Yamada T, Takeda K, Kamei T. Two cases of myelodysplastic syndrome with extramedullary polyclonal plasma cell proliferation and autoantibody production: possible role of soluble Fas antigen for production of excessive self-reactive B cells. Intern Med. 1998;37(11):973-7.
55. Okamoto T, Okada M, Mori A, Saheki K, Takatsuka H, Wada H, et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol. 1997;66(3):345-51.
56. Amin H, Jilani I, Estey E, Keating M, Dey A, Manshouri T, et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003;102(5):1866-8.
57. Shioi Y, Tamura H, Yokose N, Satoh C, Dan K, Ogata K. Increased apoptosis of circulating T cells in myelodysplastic syndromes. Leuk Res. 2007;31(12):1641-8.
58. Hamdi W, Ogawara H, Handa H, Tsukamoto N, Murakami H. Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome. Int J Lab Hematol. 2009;31 (6):630-8.
59. Melenhorst J, Eniafe R, Follmann D, Nakamura R, Kirby M, Barrett A. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol. 2002;119(1):97-105.
60. Kook H, Zeng W, Guibin C, Kirby M, Young N, Maciejewski J. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol. 2001;29 (11):1270-7.
61. Kotsianidis I, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou A, et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes. Leukemia. 2009;23(3):510-8.
62. Kordasti S, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145(1):64-72.
63. Kiladjian J, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis J, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia. 2006;20(3):463-70.
64. Epling-Burnette P, Bai F, Painter J, Rollison D, Salih H, Krusch M, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109(11):4816-24.
65. Marcondes A, Mhyre A, Stirewalt D, Kim S, Dinarello C, Deeg H. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA. 2008;105(8):2865-70.
66. Cortelezzi A, Cattaneo C, Cristiani S, Duca L, Sarina B, Deliliers GL, et al. Non-transferrinbound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J. 2000;1(3):153-8.
67. Pullarkat V. Objectives of iron chelation in myelodysplastic syndromes: more than meets the eye? Blood. 2009;114(26):5251-5.
68. Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol. 2006;55(3):251-8.
69. Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR. Iron and Mycobacterium tuberculosis infection. J Clin Virol. 2001;20(3):123-6.
70. Schaible UE, Kaufmann SH. Iron and microbial infection. Nat Rev Microbiol 2004;2 (12):946-53.
71. Weinberg ED. Microbial pathogens with impaired ability to acquire host iron. Biometals. 2000;13(1):85-9.
72. Boelaert JR, Vandecasteele SJ, Appelberg R, Gordeuk VR. The effect of the host's iron status on tuberculosis. J Infect Dis. 2007;195 (12):1745-53.
73. Pieracci FM, Barie PS. Iron and the risk of infection. Surg Infect (Larchmt). 2005;6 (Suppl 1):S41-6.
74. Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2008;42(12):799-805.
75. von Bonsdorff L, Sahlstedt L, Ebeling F, Ruutu T, Parkkinen J. Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. FEMS Immunol Med Microbiol 2003;37(1):45-51.
76. Bradley SJ, Gosriwitana I, Srichairatanakool S, Hider RC, Porter JB. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol 1997;99(2):337-43.
77. Altes A, Remacha AF, Sarda P, Sancho FJ, Sureda A, Martino R, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant. 2004;34(6):505-9.
78. Busca A, Falda M, Manzini P, D'Antico S, Valfre A, Locatelli F, et al. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: Quantification or iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant. 2010;16(1):115-22.
79. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007;110(6):1303-6.
80. Maertens J, Demuynck H, Verbeken EK, Zachée P, Verhoef GE, Vandenberghe P, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24(3):307-12.
81. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-8.
82. Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott BL, Kröger N, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome Biol Blood Marrow Transplant 2008;14(11):1217-25.
83. Greenberg P, Koller C, Cabantchik Z, Warsi G, Glynos T, Paley C, et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leukemia Res. 2010;34(12):1560-5.
84. Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993;91(5):1979-86.
85. Keijzer A, van der Valk P, Ossenkoppele GJ, van de Loosdrecht AA. Mucormycosis in a patient with low risk myelodysplasia treated with anti-tnf-alpha. Haematologica. 2006;91 (10):139-40.
86. Prokopowicz GP, Bradley SF, Kauffman CA. Indolent zygomycosis associated with deferoxamine chelation therapy. Mycoses. 1994;37(11-12):427-31.
87. Reyes HM, Tingle EJ, Fenves AZ, Spiegel J, Burton EC. Pulmonary invasive mucormycosis in a patient with secondary iron overload following deferoxamine therapy. Proc (Bayl Univ Med Cent). 2008;21(4):378-81.
88. Cordonnier C. Management of infectious complications in Hematological patients. In: Dunitz, (ed.) Text Book on Malignant Haematology. 2nd ed. London, 2005.
89. Cordonnier C, Maury S. Epidemiology and risk factors for serious infections in the stem cell transplant setting. Blood Rev. 2007; (Suppl 1)S39-42.
90. Chauncey T, Gundacker H, Shadman M, List A, Dakhil S, Erba H, et al. Sequential phase II Southwest Oncology Group studies (S0012 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with cyclosporine, in older patients with previously untreated acute myeloid leukemia. Br J Haematol. 2010;148(1):48-58.
91. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109(12):5129-35.
92. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med. 2001;135(6):412-22.
93. Cornely OA, Maertens J, Winston DJ, Perfect JR, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. Fluconazole or Itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-59.
94. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011;19(1):19-26.
95. Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica. 2001;86(8):862-70.
96. Santini V, Fenaux P, Mufti G, Hellström- Lindberg E, Silverman L, List A, et al. Management and supportive care measures for adverse events in patients with myelodys plastic syndromes treated with azacitidine. Eur J Haematol. 2010;85(2):130-8.
97. Fenaux P, Gattermann N, Seymour J, Hellström-Lindberg E, Mufti G, Duehrsen U, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149(2):244-9.
98. Merkel D, Filanovsky K, Aviv A, Gatt M, Herishanu Y, Arad A, et al. Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients American Society for Hematology Annual Meeting 2011. San Diego, 2011.
99. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14):1456-65.
100. Adès L, Boehrer S, Prebet T, Beyne-Rauzy O, Legros L, Ravoet C, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 2009;113(17):3947-52.
101. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg JH, et al. Phase 2 study of lenalidomide in transfusion-dependent, lowrisk, and intermediate-1 -risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111(1):86-93.
102. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittleman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-76.
103. Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, et al. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience. Leukemia Res. 2011;35(11):1444-8.
104. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100(4):1201-7.
105. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002; 100(13):4358-66.
106. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2002;34(7):909-17.
107. Scott BL, Park JY, Deeg HJ, Marr KA, Boeckh M, Chauncey TR, et al. Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2008;14(7):799-806.
108. Lee JH, Lee KH, Lee JH, Kim DY, Kim SH, Lim SN, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res. 2011;35(4):499-503.
109. Monselise A, Blickstein D, Ostfeld I, Segal R, Weinberger M. A case of cellulitis complicating Campylobacter jejuni subspecies jejuni bacteremia and review of the literature. Eur J Clin Microbiol Infect Dis. 2004;23(9):718-21.
110. Soravia-Dunant V, Loo V, Salit I. Aortitis due to Salmonella: report of 10 cases and comprehensive review of the literature. Clin Infect Dis. 1999;29(4):862-8.
111. Olson J, Nguyen V, Yoo J, Kuechie M. Cutaneous manifestations of Corynebacterium jeikeium sepsis. Int J Dermatol. 2009;48(8):886-8.
112. Ortin X, Jean-Martinez J, Rodriguez-Luaces M, Alvaro T, Font L. Fatal pulmonary hemorrhage in a patient with myelodysplastic syndrome and fulminant pneumonia caused by Stenotrophomonas maltophilia. Infection. 2007;35(3):201-2.
113. Fry N, Duncan J, Edwards M, Tilley R, Chitnavis D, Harman R, et al. A UK clinical isolate of Bordetella hinzii from a patient with myelodysplastic syndrome. J Med Microbiol. 2007;56(12):1700-3.
114. Zhu X, Xu J, Xiang L, Kang K. Cutaneous infectious granuloma caused by Phenylobacterium in an adult with myelodysplastic syndrome: a first case report. Am J Clin Dermatol. 2010;11(5):363-6.
115. Bay J, Tournilhac O, Ducher E, Romaszko JP, Ergani A, Bouvet A, et al. A near fatal septic transfusion reaction due to Streptococcus dysgalactiae supspecies equisimilis calls for novel safety measures. Vox Sang. 2009;96 (3):271.
116. Coutinho H, Galloway A, Ajdukiewicz K, Cleeve V. A case of Staphylococcus aureus septicaemia following platelet transfusion. J Clin Pathol. 2010;63(3):262-3.
117. Diamantidis M, Ionanidou-Papagiannnaki E, Kountouras J, Mandala E, Taspournas G, Frida-Michailidou I, et al. High prevalence of Helicobacter pylori infection in Greek patients with myelodysplastic syndromes. Acta Haematol. 2010;124(3):141-9.
118. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guidelines for the use of antiicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-93.
119. Benton N, Musaad S, Vaughan R, McLean L. Recurrent multifocal Mycobacterium kansasii infection in an immunosuppressed patient with myelodysplasia and relapsing polychondritis. Rheumatology (Oxford). 2004;43(11):1453-4.
120. Kim H, Goo J, Kim H, Lee J, Seo J, Im J. Tuberculosis in patients with myelodysplastic syndromes. Clin Radiol. 2002;57(5):408-14.
121. Komeno T, Itoh T, Ohtani K, Kamoshita M, Hasegawa Y, Hori M, et al. Disseminated nontuberculous mycobacteriosis caused by mycobacterium kansasii in a patient with myelodysplastic syndrome. Intern Med. 1996;35(4):323-6.
122. Nakada S, Sekikawa T, Takahara S, Yamazaki Y, Yamada J, Yamada H, et al. Nontuberculous atypical mycobacterial infection with progressive pancytopenia in a patient with myelodysplastic syndrome. Runsho Ketsueki. 2001;42(7):543-8.
123. Tsukada H, Chou T, Ishizuka Y, Ogawa O, Saeki T, Ito S, et al. Disseminated mycobacterium avium-intracellulare infection in a patient with myelodysplastic syndrome (refractory anemia). Am J Hematol. 1994;45 (4):325-9.
124. Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 2005;19(5):767-75.
125. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, MacBeth KJ, et al. Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. J Clin Oncol. 2011;29(18):2521-7.
126. Mele L, Ricci P, Nosari A, Tonso A, Fianci L, Cudillo L, et al. Invasive fungal infection in patients with myelodysplastic syndrome: a report of twelve cases. Leuk Lymphoma. 2002;43(8):1613-7.
127. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, et al. Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica. 2010;95(4):644-50.
128. Chandra S, Woodgyer A. Primary cutaneous zygomycosis due to Mucor circinelloides. Australas J Dermatol. 2002;43(1):39-42.
129. García-Bustínduy M, Guimerá-Martín-Neda F, Noda A, Lecuona M, Sánchez-González R, González de Mesa MJ, et al. Primary cutaneous mucormycosis: a diagnosis to consider. J Eur Acad Dermatol Venereol. 1999;12 (3):258-62.
130. Kalayjian RC, Herzig RH, Cohen AM, Hutton MC. Thrombosis of the aorta caused by mucormycosis. South Med. 1988;81(9): 1180-2.
131. Machida U, Kami M, Uozaki H, Makimura K, Yamaguchi H, Hirai H. Subacute spinal cord infarction due to zygomycotic thrombosis in a patient with myelodysplastic syndrome. Haematologica. 2000;85(9):1004-6.
132. Moses AE, Rahav G, Barenholz Y, Elidan J, Azaz B, Gillis S, et al. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin Infect Dis. 1998;26(6):1430-3.
133. Nakazato T, Nagasaki A, Nakayama T, Shinhama A, Taira N, Takasu N. Sinonasal zygomycosis in a patient with myelodysplastic syndrome following non-myeloablative allogeneic peripheral blood stem cell transplantation. Intern Med. 2007;46(22):1881-2.
134. Ng TT, Campbell CK, Rothera M, Houghton JB, Hughes D, Denning DW. Successful treatment of sinusitis caused by Cunninghamella bertholletiae. Clin Infect Dis. 1994;19(2):313-6.
135. Rozich J, Holley HJ, Henderson F, Gardner J, Nelson F. Cauda equina syndrome secondary to disseminated zygomycosis. JAMA. 1988;260(24):3638-40.
136. Takashima R, Odaka M, Watanabe Y, Hirat K, Yoshida A. Case of basilar artery occlusion caused by mucormycotic embolism in the course of myelodysplastic syndrome. Brain Nerve. 2009;61(9):1079-82.
137. Wohlrab JL, Anderson ED, Read CA. A patient with myelodyplastic syndrome, pulmonary nodules, and worsening infiltrates. Chest. 2001;120(3):1014-7.
138. Wüppenhorst N, Lee MK, Rappold E, Kayser G, Beckervordersandforth J, de With K, et al. Rhino-orbitocerebral zygomycosis caused by Conidiobolus incongruus in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4322-5.
139. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859-67.
140. De Pasqual A, Deprez M, Ghaye B, Frère P, Kaschten B, Hayette MP, et al. Invasive pulmonary mucormycosis with invasion of the thoracic spine in a patient with myelodysplastic syndrome. Rev Med Liege. 2008;63 (12):702-6.
141. Joshita S, Kitano K, Nagaya T, Kamijo A, Nakazawa K, Ishida F. Zygomycosis presenting as acute myocardial infarction during hematological malignancies. Intern Med. 2008;47(9):839-42.
142. Patterson TF, Mackool B, Gilman M, Piris A. Case 22-2009: A 59 year-old man with skin and pulmonary lesions after chemotherapy for leukemia. N Engl J Med. 2009;36(13):287-96.
143. Kim J, Kim Y, Park C, Kang J, Kim B, Woo J, et al. A case of disseminated Trichosporon beigelii infection in a patient with myelodyspalstic syndrome after chemotherapy. J Korean Med Sci. 2001;16(4):505-8.
144. Inoue Y, Onoda M, Aihara M, Koiwa K, Yamane Y, Ikezawa Z. Cryptococcal cellulitis in a patient with myelodysplastic syndrome. Acta Derm Venerol. 2011;91(2):199-200.
145. Liu P, Yang Y, Shi Z. Cryptococcal liver abscess: a case report of successful treatment with amphotericin-B and literature review. Jpn J Infect Dis. 2009;62(1):59-60.
146. Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMENA centres. Br J Haematol. 2002;117(2):379-86.
147. Matsumura Y, Shindo Y, Iinuma Y, Yamamoto M, Shirano M, Matsushima A, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including micriobiological genotypes. BMC Infect Dis. 2011;11:76.
148. Baurmann H, Schwarz T, Oertel J, Serke S, Roggendorf M, Huhn D. Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the marrow. Ann Hematol. 1992;64(1):43-5.
149. Hasle H, Heegaard E, Kerndrup G, Jensen I, Peterslund N, Hornsleth A. Parvovirus B19 infection infrequently involved in children and adults with myelodysplastic syndrome. Leuk Res. 1996;20(1):81-3.
150. Hasle H, Kerndrup G, Jacobsen BB, Heegaard E, Horsnleth A, Lillevang S. Chronic parvovirus infection mimicking myelodysplastic syndrome in a child with subclinical immunodeficiency. Am J Pediatr Hematol Oncol. 1994;16(4):329-33.
151. Yetgin S, Cetin M, Yenicesu I, Ozaltin F, Uckan D. Acute parvovirus B19 infection mimicking juvenile myelomonocytic leukemia. Eur J Haematol. 2000;65(4):276-8.
152. Yarali N, Duru F, Sipahi T, Kara A, Tezic T. Parvovirus B19 infection reminiscent of myelodysplastic syndrome in three children with chronic hemolytic anemia. Pediatr Hematol Oncol. 2000;17(6):475-82.
153. Kagialis-Girard S, Durand B, Mialou V, Pagès M, Galambrun C, Bertrand Y, et al. Human herpesvirus 6 infection and transient acquired myelodysplasia in children. Pediatr Blood Cancer. 2006;47(5):543-8.
154. Steensma D. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol. 2011;38(5):635-47.
155. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colonystimulating factor in the treatment of patients with myelodysplastic syndrome. Blood. 2000;95(4):1175-9.
156. Hellström-Lindberg E, Ahigren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow- up of 71 patients. Blood. 1998;92(1):68-75.
157. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood. 1996;87(10):4076-81.
158. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colonystimulating factor in combination with erythropoietin. Blood. 1993;82(3):737-43.
159. Negrin R, Haeuber D, Nagler A, Kobayashi Y, Sklar J, Donlon T, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 1990;76(1):36-43.
160. Rose C, Wattel E, Bastion Y, Berger E, Bauters F, Coiffier B, et al. Treatment with very lowdose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia. 1994;8(9):1458-62.
161. Shikama Y, Shichishima T, Ohto H, Jubinski PT, Maryuma Y. Neutrophil-specific reduction in the expresion of granulocytemacrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes. Br J Haematol. 2000;111(3):863-72.
162. Nagler A, Binet C, Mackichan M, Negrin R, Bangs C, Donlon T, et al. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. Blood. 1990;76(7):1299-307.
163. Verhoef G, Boogaerts M. In vivo administration of granulocyte-macrophage colony stimulating factor enhances neutrophil function in patients with myelodysplastic syndromes. Br J Haematol 1991;79(2):177-84.
164. Felzmann T, Gisslinger H, Ludwig H. Immunological findings in patients with myelodysplastic syndrome. Leuk Lymphoma. 1994;15(3-4):201-8.
165. Schuster M, Thompson J, Larson R, et al. Randomized trial of subcutaneous granulocyte- macrophage colon-stimulating factor versus observation in patients with myelodysplastic syndrome. J Cancer Res Clin Oncol. 1990;116:1079a.
166. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of recombinant human G-CSF in MDS. American Society of Hematology Annual Meeting; 1993: Blood;1993.p.196a.
167. Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, et al. Low-dose cytosine-arabinoside (LD-AraC) vs LD-AraC plus granulocyte-macrophage colony stiumating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia. 2005;19(11): 1929-33.
168. Ossenkoppele G, van der Holt B, Verhoef G, Daenen S, Verdonck L, Sonneveld P, et al. A randomized study of granulocyte colonystimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch- Belgian Hemato-Oncology Cooperative Group. Leukemia. 1999;13(8):1207-13.
169. Giagounidis A, Fenaux P, Mufti G, Muus P, Platzbecker U, Sanz G, et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol. 2008;87(5):345-52.
170. Levenga TH, Timmer-Bonte NH. Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies. Br J Haematol. 2007;138(2): 146-52.
171. Scott BL, Estey E. Management of myelodysplastic syndromes: 2008 update. Oncology. 2008;22(12):1344-68.
172. Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbath S, et al. Society's failure to protect a precious resource: antibiotics. The Lancet. 2011;378 (9788):369-71.
173. Hughes J. Preserving the lifesaving power of antimicrobial agents. JAMA. 2011;305 (10):1027-8.
174. Maertens J, Groll A, Cordonnier C, De la Camara R, Roilides E, Marchetti O. Treatment and timing in invasive mould disease. J Antimicrob Chemother 2011;66 (Suppl 1):i37-43.
175. Alanio A, Cordonnier C, Bretagne S. Azole Resistance in Aspergillus fumigatus - Current Epidemiology and Future Perspectives. Curr Fungal Infect Rep. 2011;5:168-78.
176. Howard S, Cerar D, Anderson M, Albarrag A, Fisher M, Pasqualotto A, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15(7):1068-76.
177. Leitch HA. Iron overload in the infectious risk of MDS. Drugs. 2011;71(2):155-77.
178. Spellberg B, Ibrahim A, Chin-Hong P, Kontoyannis D, Morris M, Perfect J, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67(3):715-22.
179. Almyroudis N, Segal BH. Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med. 2006;354(1):90-4.
180. Baden L. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med. 2005;353(10):1052-4.
181. Lyons R, Cosgriff T, Modi S, Gersh R, Hainsworth J, Cohn A, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27(11): 1850-6.
182. Fenaux P, Bowen D, Gattermann N, Hellström-Lindberg E, Hofmanne W, Pfeilstöcker M, et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion. Leukemia Res. 2010;34(11):1410-6